Shares of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) have been assigned a consensus recommendation of “Hold” from the ten analysts that are presently covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, one has given a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $40.80.

Several equities analysts have recently weighed in on ADMS shares. Piper Jaffray Companies reiterated an “overweight” rating and issued a $30.00 price target on shares of Adamas Pharmaceuticals in a research report on Friday, September 1st. They noted that the move was a valuation call. BidaskClub cut Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, July 19th. Zacks Investment Research upgraded Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, July 11th. Cowen and Company set a $45.00 price target on Adamas Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, August 9th. Finally, William Blair reiterated an “ourperform” rating on shares of Adamas Pharmaceuticals in a research report on Friday, August 25th.

COPYRIGHT VIOLATION NOTICE: “Analysts Set Adamas Pharmaceuticals, Inc. (ADMS) PT at $36.00” was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at https://www.watchlistnews.com/analysts-set-adamas-pharmaceuticals-inc-adms-pt-at-36-00/1578844.html.

Adamas Pharmaceuticals (NASDAQ:ADMS) last announced its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.93) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.81) by ($0.12). The company had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.03 million. Adamas Pharmaceuticals had a negative net margin of 10,499.65% and a negative return on equity of 52.91%. Adamas Pharmaceuticals’s revenue for the quarter was down 90.9% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.78) earnings per share.

Large investors have recently bought and sold shares of the stock. Tower Research Capital LLC TRC bought a new stake in Adamas Pharmaceuticals during the second quarter valued at $109,000. American International Group Inc. boosted its stake in Adamas Pharmaceuticals by 7.1% during the first quarter. American International Group Inc. now owns 10,284 shares of the specialty pharmaceutical company’s stock valued at $180,000 after buying an additional 682 shares during the period. Virtu KCG Holdings LLC bought a new stake in Adamas Pharmaceuticals during the second quarter valued at $184,000. Wells Fargo & Company MN boosted its stake in Adamas Pharmaceuticals by 28.4% during the first quarter. Wells Fargo & Company MN now owns 15,166 shares of the specialty pharmaceutical company’s stock valued at $266,000 after buying an additional 3,358 shares during the period. Finally, Trexquant Investment LP bought a new stake in Adamas Pharmaceuticals during the first quarter valued at $287,000. 69.24% of the stock is owned by institutional investors.

Adamas Pharmaceuticals Company Profile

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

Analyst Recommendations for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Ratings for Adamas Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.